MG
GRCL

Michael Gelband’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Michael Gelband’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-87,529
Closed -$481K – 2413
2022
Q2 		$481K Buy
+87,529
New +$272K 0.01% 1378
2021
Q4 		– Sell
-14,700
Closed -$204K – 2724
2021
Q3 		$204K Buy
+14,700
New +$174K ﹤0.01% 1772

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $7.06B AUM 36.47% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Michael Gelband's GRCL Position: Q3 2022 in Review

Michael Gelband sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q3 2022, closing a stake of 87,529 shares — an estimated $481K sold.

Michael Gelband first reported a position in GRCL in Q3 2021 and held it in 2 quarters. The position peaked at $481K in Q2 2022. 33 funds tracked by Wall St. Rank hold GRCL as of Q3 2022.

  • Michael Gelband reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Michael Gelband sold 87,529 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2022, an estimated $481K.
  • Michael Gelband first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2021 and held it in 2 quarters.
  • Michael Gelband's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $481K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.